Pfizer boasted that the FDA had granted “priority review” for a drug, crizotinib, that treats some types of lung cancer.

辉瑞（Pfizer）自称已获得食品及药物管理局对药品crizotinib的“优先审核”。 （crizotinib是治疗某些类型肺癌的药品）。

youdao

Pfizer’s crizotinib attacks a protein encoded by a gene found in fewer than 5% of patients with non-small-cell lung cancer.

辉瑞公司的crizotinib攻击某种蛋白质，这种蛋白质由在不到5%的非小细胞肺癌患者中发现的一种基因编码。

youdao

Pfizer's crizotinib attacks a protein encoded by a gene found in fewer than 5% of patients with non-small-cell lung cancer.

Pfizer的crizotinib专门攻击某种基因转录的蛋白，只有少于5%的非小细胞肺癌患者具有这种基因。 Roche的vemurafenib通过阻断基因B-RAF的变异体抵抗晚期黑色素瘤。

youdao

He says that some patients may benefit from the crizotinib drug even even after some of their tumors start to regrow.

FORBES: Pfizer Drug Powers Cancer Treatment Into The DNA Age

One is crizotinib, for 5% of patients with non-small cell lung cancer.

FORBES: The Biggest Controversies Facing Pfizer

Most notably, we completed U.S. and Japanese filings for crizotinib in ALK-positive non-small cell lung cancer and U.S. and EU filings for axitinib in advanced renal cell carcinoma.

FORBES: Pfizer Suffers Loss Of Exclusivity, Braces Itself For Lipitor Expiration